AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 773414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 12
Study 773414 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% ointment
Number of subjects: 12
Study 31587084 — intervention group
Group type: EXPERIMENTAL
Intervention: AA homozygotes (risk A allele)
Number of subjects: 290
Study 31587084 — intervention group
Group type: COMPARATOR
Intervention: G allele carriers
Number of subjects: 290
Study 31326433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide 10 mg
Number of subjects: 18
Study 31326433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide 1 mg
Number of subjects: 18
Study 31326433 — intervention group
Group type: EXPERIMENTAL
Intervention: Glepaglutide (both doses)
Number of subjects: 18
Study 26822791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg, twice daily)
Number of subjects: 13
Study 26822791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 25231008 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol active arm
Number of subjects: 0
Study 25231008 — intervention group
Group type: EXPERIMENTAL
Intervention: dropout patterns
Number of subjects: 0
Study 25231008 — intervention group
Group type: EXPERIMENTAL
Intervention: disease progression
Number of subjects: 0
Study 24062400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after induction cycle 1
Number of subjects: 471
Study 24062400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after induction cycle 2
Number of subjects: 471
Study 24062400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after consolidation therapy
Number of subjects: 471
Study 22288153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladasten (15 mg)
Number of subjects: 0
Study 22288153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19637398 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15-30 mg/day)
Number of subjects: 18
Study 19637398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22129365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months; dose reduction to 4 mg and re-escalation to 8 mg allowed annually
Number of subjects: 864
Study 22129365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months
Number of subjects: 864
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 665
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 665
Study 15872201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients with ischemic heart disease)
Number of subjects: 665
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (in patients with ischemic heart disease)
Number of subjects: 665
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Amiodarone and Sotalol
Number of subjects: 665
Study 15872201 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 665
Study 12740449 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention plus parenting support (OPPS) intervention
Number of subjects: 43
Study 12740449 — intervention group
Group type: COMPARATOR
Intervention: Parenting support (PS) only
Number of subjects: 43
Study 10541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction regimen (approximately 25% less fluid prescribed)
Number of subjects: 90
Study 10541949 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen (60 ml/kg on day 1, increasing to 150 ml/kg by day 7)
Number of subjects: 90
Study 10541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid intake
Number of subjects: 90
Study 7775858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (46% fat, 38% carbohydrate) for 6 weeks
Number of subjects: 43
Study 7775858 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (24% fat, 60% carbohydrate) for 6 weeks
Number of subjects: 43
Study 2109073 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms q.i.d.
Number of subjects: 420
Study 2109073 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 420
Study 2109073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 7471925 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-training program
Number of subjects: 19
Study 7471925 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 30478067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy for 28 days
Number of subjects: 40
Study 29064792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg once a day
Number of subjects: 50
Study 25296247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 25296247 — intervention group
Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 40
Study 25296247 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug failure
Number of subjects: 40
Study 25296247 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hypertension
Number of subjects: 40
Study 24004700 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 743
Study 24004700 — intervention group
Group type: COMPARATOR
Intervention: Physician chart reminder
Number of subjects: 743
Study 24004700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed education/FIT
Number of subjects: 743
Study 24004700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed education/FIT plus phone call
Number of subjects: 743
Study 21959802 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP K90 160 mg/tablet
Number of subjects: 0
Study 21959802 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP K90 partially replaced with different gums
Number of subjects: 0
Study 21959802 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP K90 and gum tragacanth
Number of subjects: 0
Study 21959802 — intervention group
Group type: COMPARATOR
Intervention: Commercially available Diclofenac Sodium SR
Number of subjects: 0
Study 17786445 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing oxaliplatin and infusional 5‐fluorouracil (5‐FU)
Number of subjects: 0
Study 17786445 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and 5‐FU
Number of subjects: 0
Study 17786445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with irinotecan
Number of subjects: 0
Study 16541114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg oral daily tamsulosin (group 1, n=59)
Number of subjects: 118
Study 16541114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2, n=59)
Number of subjects: 118
Study 14506138 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-weekly schedule of gemcitabine (1500 mg/m²) and cisplatin (90 mg/m²)
Number of subjects: 73
Study 14506138 — intervention group
Group type: COMPARATOR
Intervention: Weekly schedule of gemcitabine and cisplatin
Number of subjects: 73
Study 14506138 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-weekly schedule
Number of subjects: 73
Study 14506138 — intervention group
Group type: COMPARATOR
Intervention: Weekly schedule
Number of subjects: 73
Study 11038435 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal (fed state)
Number of subjects: 0
Study 11038435 — intervention group
Group type: COMPARATOR
Intervention: Fasted state (control)
Number of subjects: 0
Study 8850048 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical formulations containing clobetasol propionate, doxepin hydrochloride, metronidazole, mupirocin, oxiconazole nitrate, and terbinafine hydrochloride
Number of subjects: 108
Study 8850048 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride cream vehicle
Number of subjects: 108
Study 8850048 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene and ketoconazole
Number of subjects: 108
Study 1626168 — intervention group
Group type: COMPARATOR
Intervention: Dolotren (D) 100 mg, administered b.i.d. for 15 days
Number of subjects: 9
Study 1626168 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolotren Retard (DR) 100 mg, administered once a day for 15 days
Number of subjects: 9
Study 1626168 — intervention group
Group type: COMPARATOR
Intervention: Both D and DR
Number of subjects: 9
Study 6844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 65
Study 6844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical psychotherapy
Number of subjects: 65
Study 6844471 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nurse-led psychotherapy (without training)
Number of subjects: 65
Study 6844471 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 65
Study 30243810 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 276
Study 30243810 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine evacuation
Number of subjects: 276
Study 30243810 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric use of methotrexate
Number of subjects: 276
Study 27631270 — intervention group
Group type: COMPARATOR
Intervention: Conventional ISB (ISB with the conventional approach, n=31)
Number of subjects: 92
Study 27631270 — intervention group
Group type: COMPARATOR
Intervention: C5 ISB (ISB with the C5 approach, n=30)
Number of subjects: 92
Study 27631270 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (no ISB, n=31)
Number of subjects: 92
Study 24146195 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (LMA)
Number of subjects: 76
Study 24146195 — intervention group
Group type: COMPARATOR
Intervention: Plain endotracheal tube
Number of subjects: 76
Study 21928871 — intervention group
Group type: EXPERIMENTAL
Intervention: Postevent assessment (n = 296)
Number of subjects: 492
Study 21928871 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 196)
Number of subjects: 492
Study 20430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0.3 body height
Number of subjects: 61
Study 20430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0.05 body height
Number of subjects: 61
Study 20430326 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0 body height
Number of subjects: 61
Study 18700424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at -5 cm H2O
Number of subjects: 10
Study 18700424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 0 cm H2O
Number of subjects: 10
Study 18700424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at +5 cm H2O
Number of subjects: 10
Study 18700424 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at +10 cm H2O
Number of subjects: 10
Study 15882483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits
Number of subjects: 47
Study 15882483 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 47
Study 12587887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity warm-up (5 sprints at 200% VO2max for 10 s with 50 s recovery at 55% VO2max)
Number of subjects: 7
Study 12587887 — intervention group
Group type: COMPARATOR
Intervention: Continuous warm-up (15 min at approximately 65% VO2max)
Number of subjects: 7
Study 14601484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CUS)
Number of subjects: 62
Study 14601484 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral obesity (OTY)
Number of subjects: 62
Study 14601484 — intervention group
Group type: EXPERIMENTAL
Intervention: Addison's disease (AD)
Number of subjects: 62
Study 14601484 — intervention group
Group type: COMPARATOR
Intervention: Healthy women (KON)
Number of subjects: 62
Study 10201278 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 8519562 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration using e‐PTFE membranes (Gore‐Tex)
Number of subjects: 9
Study 8519562 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 9
Study 2136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80
Study 2136070 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 80
Study 7416612 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered epinephrine
Number of subjects: 48
Study 7416612 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol
Number of subjects: 48
Study 7416612 — intervention group
Group type: COMPARATOR
Intervention: Intravenously administered aminophylline
Number of subjects: 48
Study 31962198 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole breast irradiation (WBI) after endocrine therapy (ET)
Number of subjects: 869
Study 31962198 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone (observation)
Number of subjects: 869
Study 31202539 — intervention group
Group type: EXPERIMENTAL
Intervention: LA‐FINDRISC
Number of subjects: 3061
Study 31202539 — intervention group
Group type: COMPARATOR
Intervention: O‐FINDRISC
Number of subjects: 3061
Study 28502637 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged disposable washcloths
Number of subjects: 2637
Study 28502637 — intervention group
Group type: COMPARATOR
Intervention: Traditional bath basins
Number of subjects: 2637
Study 25660465 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community-based counselling intervention with two pregnancy and five postnatal home visits delivered by community health workers.
Number of subjects: 4137
Study 25660465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4137
Study 22935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 16
Study 22935028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion
Number of subjects: 16
Study 22935028 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 20602715 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD) and increased to 120 mg QD at week 7 if < 30% pain reduction
Number of subjects: 256
Study 20602715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 19583755 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (GA)
Number of subjects: 104
Study 19583755 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 16829208 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitor
Number of subjects: 0
Study 16829208 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 15651152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT) screening
Number of subjects: 0
Study 15651152 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 0
Study 15651152 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy and irigography
Number of subjects: 0
Study 11707042 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stage head‐up tilt table test (HUT) with infusion of 3.44 microg/kg per hour of nitroglycerin
Number of subjects: 37
Study 11707042 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional multistage test with infusion of nitroglycerin from 1.72 microg/kg per hour to 5.16 microg/kg per hour
Number of subjects: 37
Study 11707042 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects during single stage HUT
Number of subjects: 37
Study 11707042 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects during multistage HUT
Number of subjects: 37
Study 11707042 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of single stage HUT
Number of subjects: 37
Study 9597560 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day testosterone transdermal patch (T)
Number of subjects: 21
Study 9597560 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/day testosterone transdermal patches (R)
Number of subjects: 21
Study 7513516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo EGb 761 (Tebonin) + HAES
Number of subjects: 80
Study 7513516 — intervention group
Group type: COMPARATOR
Intervention: Naftidrofuryl (Dusodril) + HAES
Number of subjects: 80
Study 3280519 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop method
Number of subjects: 50
Study 3280519 — intervention group
Group type: COMPARATOR
Intervention: Capped syringe method
Number of subjects: 50
Study 31240541 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP therapy
Number of subjects: 75
Study 31240541 — intervention group
Group type: COMPARATOR
Intervention: Nasal strips (control)
Number of subjects: 75
Study 29943522 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 52
Study 29943522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 27537606 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic defocus group (MDG) with additional -3D lenses
Number of subjects: 51
Study 27537606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopic defocus group (HDG) with additional +3D lenses
Number of subjects: 51
Study 27537606 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with full correction
Number of subjects: 51
Study 25131453 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation superimposed onto voluntary contractions (NMES+; n=22)
Number of subjects: 89
Study 25131453 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES; n=22)
Number of subjects: 89
Study 25131453 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional contraction (VC; n=22)
Number of subjects: 89
Study 25131453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 22776011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (ESCAPE)
Number of subjects: 26
Study 20137138 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of mesenchymal stem cells (MSCs)
Number of subjects: 15
Study 20137138 — intervention group
Group type: COMPARATOR
Intervention: Control (HSCT only)
Number of subjects: 15
Study 18713887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% end-tidal concentration in air/oxygen
Number of subjects: 27
Study 18713887 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of ketoprofen 1 mg/kg and fentanyl 1 microg/kg
Number of subjects: 27
Study 18713887 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements before premedication with midazolam 0.1 mg/kg IV
Number of subjects: 27
Study 15878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed sequence learning
Number of subjects: 0
Study 15878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Random sequence learning
Number of subjects: 0
Study 15878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralesional hand performance
Number of subjects: 0
Study 15878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilesional hand performance
Number of subjects: 0
Study 15878728 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tapping rate
Number of subjects: 0
Study 15878728 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 15250818 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10890862 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lodoxamide ophthalmic solution 0.1% (LOS)
Number of subjects: 30
Study 10890862 — intervention group
Group type: COMPARATOR
Intervention: Topical cromolyn sodium ophthalmic solution 4% (CSO)
Number of subjects: 30
Study 8931233 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for acute embolus occlusion of the SMA (ligating the distal end of the SMA and using a Fogarty balloon catheter to remove clots).
Number of subjects: 3
Study 1390326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 26
Study 1390326 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once a day
Number of subjects: 26
Study 2996906 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline
Number of subjects: 6
Study 2996906 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms/ml pentoxifylline
Number of subjects: 6
Study 2996906 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6
Study 3298328 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 0
Study 3298328 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 29570579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sprint training (RST) with sled-equivalent resistive loads of ∼45% body mass
Number of subjects: 20
Study 29570579 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sprints (URS)
Number of subjects: 20
Study 30325849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption device (CytoSorb) used in 17 patients
Number of subjects: 35
Study 30325849 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemoadsorption device used in 18 patients)
Number of subjects: 35
Study 28611006 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily for one year
Number of subjects: 200
Study 28611006 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10mg daily for one year
Number of subjects: 200
Study 25179689 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 250 mg
Number of subjects: 1341
Study 25179689 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 500 mg
Number of subjects: 1341
Study 25179689 — intervention group
Group type: COMPARATOR
Intervention: palonosetron 0.25 mg
Number of subjects: 1341
Study 24617228 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture with long needle (75 mm) at Guanyuan (CV 4)
Number of subjects: 132